EPR signal reduction kinetic of several nitroxyl derivatives in blood in vitro and in vivo. 2009

Zhivko Zhelev, and Ken-Ichiro Matsumoto, and Veselina Gadjeva, and Rumiana Bakalova, and Ichio Aoki, and Antoaneta Zheleva, and Kazunori Anzai
Department of Biophysics, Molecular Imaging Center, National Institute of Radiological Sciences, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan. zh_zhelev@yahoo.com

The present study is focused on the mechanism(s) of electron-paramagnetic resonance (EPR) signal reduction kinetic of several nitroxyl radicals and nitroxyl-labeled anticancer drugs in physiological solutions in the context of their application for evaluation of oxidation/reduction status of blood and tissues--an important step in biomedical diagnostics and planning of therapy of many diseases. The nitroxyl derivatives were characterized with different size and water-solubility. Some of them are originally synthesized. In buffer, in the absence of reducing and oxidizing equivalents, the EPR signal intensity of all nitroxyls was constant with the time. In serum and cell cultured medium, in an absence of cells and in a negligible amount of reducing and oxidizing equivalents, there was no significant EPR signal reduction, too. In vitro (in freshly isolated blood samples), the EPR signal intensity was characterized with slow decrease within 30 min, presumably as a result of interaction between the nitroxyl derivative and blood cells. The EPR spectrum of hydrophobic nitroxyls showed a slight anisotropy in cell-containing solutions and it did not changed in non-cell physiological solutions. This suggests for a limited motion of more hydrophobic nitroxyls through their preferable location in cell membranes. In vivo (in the bloodstream of mice under anesthesia), the EPR signal reduction kinetic was characterized by two phases: i) a rapid enhancement within 30 s as a result of increasing of nitroxyl concentration in the bloodstream after its intravenous injection, followed by ii) a rapid decrease (approximately 80-100%) within 2-5 min, presumably as a result of transportation of nitroxyl in the tissues. The hydrophobic nitroxyls were characterized with stronger and faster decrease in EPR signal intensity in the blood in vivo, as a result of their higher cell permeability, rapid clearance from the bloodstream and/or transportation in the surrounding tissues. The hydrophilic nitroxyls persist in the bloodstream (in their radical form) for a comparatively long time. The data suggest that the hydrophobic cell-permeable nitroxyl derivatives are most appropriate for evaluation of cell and tissue oxidation/reduction status, while the hydrophilic nitroxyls (impermeable for cell membranes or with very slow cell permeability) are most appropriate for evaluation of oxidation/reduction status of blood using EPR imaging.

UI MeSH Term Description Entries
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D009038 Motion Physical motion, i.e., a change in position of a body or subject as a result of an external force. It is distinguished from MOVEMENT, a process resulting from biological activity. Motions
D009589 Nitrogen Oxides Inorganic oxides that contain nitrogen. Nitrogen Oxide,Oxide, Nitrogen,Oxides, Nitrogen
D010084 Oxidation-Reduction A chemical reaction in which an electron is transferred from one molecule to another. The electron-donating molecule is the reducing agent or reductant; the electron-accepting molecule is the oxidizing agent or oxidant. Reducing and oxidizing agents function as conjugate reductant-oxidant pairs or redox pairs (Lehninger, Principles of Biochemistry, 1982, p471). Redox,Oxidation Reduction
D010539 Permeability Property of membranes and other structures to permit passage of light, heat, gases, liquids, metabolites, and mineral ions. Permeabilities
D004578 Electron Spin Resonance Spectroscopy A technique applicable to the wide variety of substances which exhibit paramagnetism because of the magnetic moments of unpaired electrons. The spectra are useful for detection and identification, for determination of electron structure, for study of interactions between molecules, and for measurement of nuclear spins and moments. (From McGraw-Hill Encyclopedia of Science and Technology, 7th edition) Electron nuclear double resonance (ENDOR) spectroscopy is a variant of the technique which can give enhanced resolution. Electron spin resonance analysis can now be used in vivo, including imaging applications such as MAGNETIC RESONANCE IMAGING. ENDOR,Electron Nuclear Double Resonance,Electron Paramagnetic Resonance,Paramagnetic Resonance,Electron Spin Resonance,Paramagnetic Resonance, Electron,Resonance, Electron Paramagnetic,Resonance, Electron Spin,Resonance, Paramagnetic
D005609 Free Radicals Highly reactive molecules with an unsatisfied electron valence pair. Free radicals are produced in both normal and pathological processes. Free radicals include reactive oxygen and nitrogen species (RONS). They are proven or suspected agents of tissue damage in a wide variety of circumstances including radiation, damage from environment chemicals, and aging. Natural and pharmacological prevention of free radical damage is being actively investigated. Free Radical
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D012995 Solubility The ability of a substance to be dissolved, i.e. to form a solution with another substance. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed) Solubilities

Related Publications

Zhivko Zhelev, and Ken-Ichiro Matsumoto, and Veselina Gadjeva, and Rumiana Bakalova, and Ichio Aoki, and Antoaneta Zheleva, and Kazunori Anzai
October 2009, Free radical biology & medicine,
Zhivko Zhelev, and Ken-Ichiro Matsumoto, and Veselina Gadjeva, and Rumiana Bakalova, and Ichio Aoki, and Antoaneta Zheleva, and Kazunori Anzai
December 2010, Free radical biology & medicine,
Zhivko Zhelev, and Ken-Ichiro Matsumoto, and Veselina Gadjeva, and Rumiana Bakalova, and Ichio Aoki, and Antoaneta Zheleva, and Kazunori Anzai
January 1968, Photochemistry and photobiology,
Zhivko Zhelev, and Ken-Ichiro Matsumoto, and Veselina Gadjeva, and Rumiana Bakalova, and Ichio Aoki, and Antoaneta Zheleva, and Kazunori Anzai
November 1982, Antibiotiki,
Zhivko Zhelev, and Ken-Ichiro Matsumoto, and Veselina Gadjeva, and Rumiana Bakalova, and Ichio Aoki, and Antoaneta Zheleva, and Kazunori Anzai
January 2012, Journal of magnetic resonance (San Diego, Calif. : 1997),
Zhivko Zhelev, and Ken-Ichiro Matsumoto, and Veselina Gadjeva, and Rumiana Bakalova, and Ichio Aoki, and Antoaneta Zheleva, and Kazunori Anzai
November 2002, Biochimica et biophysica acta,
Zhivko Zhelev, and Ken-Ichiro Matsumoto, and Veselina Gadjeva, and Rumiana Bakalova, and Ichio Aoki, and Antoaneta Zheleva, and Kazunori Anzai
February 1994, Magnetic resonance in medicine,
Zhivko Zhelev, and Ken-Ichiro Matsumoto, and Veselina Gadjeva, and Rumiana Bakalova, and Ichio Aoki, and Antoaneta Zheleva, and Kazunori Anzai
July 1997, Biochemistry,
Zhivko Zhelev, and Ken-Ichiro Matsumoto, and Veselina Gadjeva, and Rumiana Bakalova, and Ichio Aoki, and Antoaneta Zheleva, and Kazunori Anzai
January 1995, Journal of drug targeting,
Zhivko Zhelev, and Ken-Ichiro Matsumoto, and Veselina Gadjeva, and Rumiana Bakalova, and Ichio Aoki, and Antoaneta Zheleva, and Kazunori Anzai
January 1985, Neoplasma,
Copied contents to your clipboard!